3 completed, 1 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Retinal Neovascularization: new trials by email Literature Review of Retinal Neovascularization trials Research Report on Retinal Neovascularization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin bevacizumab with oral curcumin, bevacizumab with oral placebo - Diabetic Macular Edema, Macular Edema | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 52 | 2021-10-10 | 2024-09-19 |
| Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy Brolucizumab 6 mg, Panretinal photocoagulation laser - Proliferative Diabetic Retinopathy | Phase 3 | Completed | Novartis Pharmaceuticals | 689 | 2020-11-19 | 2025-10-16 |
| Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) - Retina, Telangiectasis | Phase 3 | Completed | University of Sao Paulo | 31 | 2006-01-01 | 2008-07-23 |
| Krypton-Argon Regression of Neovascularization Study (KARNS) Blue-Green Argon Laser Treatment, Red Krypton Laser Treatment - Diabetic Retinopathy, Retinal Neovascularization | Phase 3 | Completed | National Eye Institute (NEI) | 1984-12-01 | 2005-06-24 |
Diabetic Retinopathy (2) · Diabetes Mellitus (1) · Disease (1) · Macular Edema (1) · Telangiectasis (1)
Eye Diseases (4) · Metaplasia (4) · Neovascularization, Pathologic (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Retinal Diseases (4) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Diabetes Complications (2) · Diabetic Angiopathies (2) · Endocrine System Diseases (2) · Diabetes Mellitus (1) · Glucose Metabolism Disorders (1) · Macular Degeneration (1) · Metabolic Diseases (1)
Bevacizumab (1) · Curcumin (1) · brolucizumab (1)
Isfahan University of Medical Sciences (1) · National Eye Institute (NEI) (1) · Novartis Pharmaceuticals (1) · University of Sao Paulo (1)
Brazil (2) · Argentina (1) · Australia (1) · Canada (1) · Chile (1) · China (1) · India (1) · Iran (1) · Japan (1) · Mexico (1) · Philippines (1) · Puerto Rico (1) · Russia (1) · South Korea (1) · Taiwan (1)
Otacilio O Maia Jr, M.D. (1) · Walter Y Takahashi, M.D. (1)